BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30001427)

  • 1. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    Schaefer B; Viveiros A; Al-Zoairy R; Blach S; Brandon S; Razavi H; Dorn L; Finkenstedt A; Effenberger M; Graziadei I; Sarcletti M; Tilg H; Zoller H
    PLoS One; 2018; 13(7):e0200750. PubMed ID: 30001427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A micro-elimination approach to addressing hepatitis C in Turkey.
    Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
    BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forecasting the disease burden of chronic hepatitis C virus in Poland.
    Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
    PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease burden of chronic hepatitis C in Brazil.
    Ferreira PR; Brandão-Mello CE; Estes C; Gonçales Júnior FL; Coelho HS; Razavi H; Cheinquer H; Wolff FH; Ferraz ML; Pessoa MG; Mendes-Correa MC
    Braz J Infect Dis; 2015; 19(4):363-8. PubMed ID: 26051505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
    PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus-related chronic liver disease.
    Tokita H; Murai S; Kamitsukasa H; Yagura M; Harada H; Takahashi M; Okamoto H
    J Med Virol; 2002 Aug; 67(4):501-9. PubMed ID: 12115995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
    Aljumah AA; Abaalkhail F; Al-Ashgar H; Assiri A; Babatin M; Al Faleh F; Alghamdi A; Al-Hakeem R; Hashim A; Alqutub A; Razavi H; Sanai FM; Al-Swat K; Schmelzer J; Altraif I
    Saudi J Gastroenterol; 2016; 22(4):269-81. PubMed ID: 27488321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    Shiha G; Soliman R; Mikhail NNH; Easterbrook P
    J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of TT virus infection in patients with chronic hepatitis C.
    Zein NN; Arslan M; Li H; Charlton MR; Gross JB; Poterucha JJ; Therneau TM; Kolbert CP; Persing DH
    Am J Gastroenterol; 1999 Oct; 94(10):3020-7. PubMed ID: 10520863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and hepatitis B-related mortality in Spain.
    García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
    Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
    PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
    Bird SM; Goldberg DJ; Hutchinson SJ
    J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in Asia: when East meets West.
    Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.